JPMorgan Chase Financial Company LLC, with JPMorgan Chase & Co. as the guarantor, has announced the offering of a new structured investment product. The notes, with a minimum denomination of $1,000, are linked to the performance of the S&P 500 Index and the SPDR S&P Biotech ETF. The notes offer a contingent interest rate of at least 8.00% per annum, payable semiannually, provided certain conditions are met. The pricing date for the notes is set for July 19, 2024, with a final review date on July 19, 2027, and maturity on July 22, 2027. The notes include an early redemption option by the issuer on any semiannual interest payment date, excluding the final one. The payment at maturity is contingent on the performance of the underlyings, with a...Show More

JPMorgan Chase Financial Company LLC, with JPMorgan Chase & Co. as the guarantor, has announced the offering of a new structured investment product. The notes, with a minimum denomination of $1,000, are linked to the performance of the S&P 500 Index and the SPDR S&P Biotech ETF. The notes offer a contingent interest rate of at least 8.00% per annum, payable semiannually, provided certain conditions are met. The pricing date for the notes is set for July 19, 2024, with a final review date on July 19, 2027, and maturity on July 22, 2027. The notes include an early redemption option by the issuer on any semiannual interest payment date, excluding the final one. The payment at maturity is contingent on the performance of the underlyings, with a trigger value set at 60.00% of their initial value. If the final value of either underlying is less than its trigger value and the notes have not been redeemed early, investors could lose a significant portion, up to all, of their principal. The estimated value of the notes at the time of setting their terms will be no less than $940.00 per $1,000 principal amount note. Investors are warned of the credit risks associated with both the issuer and the guarantor, and the potential for loss, as the notes do not guarantee a return of principal or interest payments. The notes' appreciation potential is capped at the sum of any contingent interest payments, and they carry risks related to the biotechnology industry and market volatility. Secondary market liquidity is not guaranteed, and the notes may be subject to significant losses if sold before maturity.